Cancers
Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
By Silvia Marchesi, Paolo Ambrosini, Chiara Cavalli and 19 others.
Abstract
Introduction
First-line treatment options for EGFR-mutated NSCLC have expanded beyond osimertinib monotherapy following the FLAURA2 and MARIPOSA trials, which demonstrated improved long-term outcomes with combination strategies, albeit with increased toxicities. Given that randomized controlled trials (RCTs) typically enroll highly selected patients (pts), evaluating the representativeness of these cohorts in real-world (RW) practice is essential to inform RCT applicability.
Methods
We retrospectively identified patients with EGFR-mutated advanced NSCLC treated with first-line osimertinib at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, between January 2019 and August 2025. Clinical characteristics were collected, and eligibility for FLAURA, FLAURA2, and MARIPOSA was assessed according to the respective trial criteria. For survival analyses, patients were classified as trial-eligible or trial-ineligible according to FLAURA eligibility criteria, as all patients received first-line osimertinib.